Hence, the extrapancreatic actions of GIPR signaling extend to the attenuation of gut inflammation, findings with potential translational relevance for clinical strategies modulating GIPR action in people with type 2 diabetes or obesity. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.